LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Unique Gene Detects Mycobacterium Tuberculosis in Clinical Sputum

By LabMedica International staff writers
Posted on 13 Oct 2021
Print article
Image: The GeneXpert MTB/RIF assay for tuberculosis and rifampicin resistance was compared with unique gene to detect Mycobacterium tuberculosis (Photo courtesy of Cepheid)
Image: The GeneXpert MTB/RIF assay for tuberculosis and rifampicin resistance was compared with unique gene to detect Mycobacterium tuberculosis (Photo courtesy of Cepheid)
Tuberculosis (TB) is a common infectious disease caused by Mycobacterium tuberculosis (MTB). The main organ infected by MTB is the lung, but many other tissues or organs can be affected, such as the bone and pleura. Two million people die of MTB infection each year due to poor quality of life and lack of awareness.

An early and accurate diagnosis of TB is the critical factor for controlling and effectively treating the epidemic. Molecular detection, sputum-smear microscopy, and culture-based methods are widely used to diagnose TB in the clinic. The benefits of molecular diagnosis are rapidity, specificity, and high sensitivity.

Health Scientists at the Kunming University of Science and Technology (Kunming, China) collected a total of 232 clinical sputum samples from TB patients by physicians from January 2019 to December 2020. Sputum from all patients was subjected to the BACT MGIT-960 test (Becton-Dickinson, Brea, CA, USA) and Gene Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA).

A total of 173 genome sequences of Mycobacterium were downloaded and analyzed and a specific MTB gene was selected. The TB18.5 gene was considered a specific gene of the MTB strains and TB18.5 primers were designed. One-step PCR was performed in a 20 µL reaction volume, including 3 µL of DNA extracted from sputum, 10 µl of 2× TSINGKE Master Mix, and 0.3 µM each of the myco-F1 and myco-R1 primers and nested PCR was also performed. Six common clinical pathogens were used as negative controls to investigate the specificity of the TB18.5 gene and the primers.

The investigators reported that the results showed that 195 (84.05%), 182 (78.45%), and 162 (69.83%) samples were identified as MTB using nested PCR, the Gene Xpert MTB/RIF assay, and the BACTEC MGIT-960 CULTURE test, respectively. Although the nested PCR-positive ratio was the highest among the three methods, no statistical difference was identified between results of nested PCR and Gene Xpert MTB/RIF assay. However, there were significant difference between results of BACTEC MGIT-960 CULTURE test and nested PCR or Gene Xpert MTB/RIF assay.

The authors concluded that the TB18.5 gene, which was identified as a unique gene in MTB strains, was used to evaluate MTB infections. The optimized nested PCR/nested qRT-PCR method was established to detect MTB in clinical sputum samples, which showed higher positive ratio than Xpert MTB/RIF assay and the BACTEC MGIT-960 CULTURE test. Therefore, it is benefit for TB patients to obtain early and sensitively diagnose and treatment by using this nest-PCR method. The study was published on September 30, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
Kunming University of Science and Technology
Becton-Dickinson
Cepheid


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Centromere B Assay
Centromere B Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.